IOBT Company Profile and Key Details
NASDAQ : IOBT
IO Biotech
$0.01
-0.00469-27.59%
At Close 4:00 PMNot Actively Trading
61.19
BESG ScoreESG Rating
Price Chart
Stock Price Today
IO Biotech, Inc. (IOBT) stock declined over -27.59%, trading at $0.01 on NASDAQ, down from the previous close of $0.02. The stock opened at $0.02, fluctuating between $0.01 and $0.02 in the recent session.
Stock Snapshot
0.017
Prev. Close
885.69K
Market Cap
0.0082
Day Low
-0.05352173913043478
P/E Ratio
-0.23
EPS (TTM)
-1.09
Cash Flow per Share
0.02
Open
71.95M
Number of Shares
0.0168
Day High
74.79%
Free Float in %
2.02
Book Value
3.06M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 06, 2026 | 0.03 | 0.06 | 0.03 | 0.05 | 354.46M |
| Apr 02, 2026 | 0.03 | 0.04 | 0.03 | 0.03 | 39.01M |
| Apr 01, 2026 | 0.05 | 0.05 | 0.03 | 0.04 | 29.59M |
| Mar 31, 2026 | 0.05 | 0.06 | 0.04 | 0.06 | 62.97M |
| Mar 30, 2026 | 0.20 | 0.20 | 0.17 | 0.17 | 1.11M |
| Mar 27, 2026 | 0.21 | 0.21 | 0.19 | 0.19 | 657.96K |
| Mar 25, 2026 | 0.19 | 0.21 | 0.19 | 0.19 | 649.52K |
| Mar 24, 2026 | 0.20 | 0.21 | 0.19 | 0.19 | 996.67K |
| Mar 23, 2026 | 0.18 | 0.22 | 0.18 | 0.21 | 1.75M |
| Mar 20, 2026 | 0.19 | 0.19 | 0.18 | 0.18 | 970.06K |
| Mar 19, 2026 | 0.18 | 0.19 | 0.17 | 0.19 | 1.17M |
| Mar 18, 2026 | 0.17 | 0.19 | 0.16 | 0.18 | 1.43M |
| Mar 17, 2026 | 0.17 | 0.19 | 0.16 | 0.18 | 2.44M |
| Mar 16, 2026 | 0.19 | 0.20 | 0.14 | 0.18 | 5.54M |
| Mar 13, 2026 | 0.24 | 0.24 | 0.19 | 0.19 | 3.2M |
| Mar 12, 2026 | 0.24 | 0.25 | 0.22 | 0.22 | 2.99M |
| Mar 11, 2026 | 0.27 | 0.29 | 0.25 | 0.25 | 3.18M |
| Mar 10, 2026 | 0.30 | 0.31 | 0.25 | 0.27 | 1.9M |
| Mar 09, 2026 | 0.32 | 0.33 | 0.28 | 0.28 | 2.14M |
| Mar 06, 2026 | 0.31 | 0.33 | 0.30 | 0.30 | 722.53K |
Contact Details
About Company
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.
Company Information
| Employees | 80 |
| Beta | 0.89 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-4.64-0.50%
argenx SE$915.30REGN-13.35-1.97%
Regeneron Pharmaceuticals, Inc.$662.88MDGL20.04+3.67%
Madrigal Pharmaceuticals, Inc.$565.40UTHR-9.36-1.66%
United Therapeutics Corporation$554.34VRTX-23.82-4.56%
Vertex Pharmaceuticals Incorporated$498.43KRYS6.8+1.84%
Krystal Biotech, Inc.$375.40PRAX9.04+2.79%
Praxis Precision Medicines, Inc.$332.99KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY1.91+0.59%
Alnylam Pharmaceuticals, Inc.$323.50LGND-4.55-1.42%
Ligand Pharmaceuticals Incorporated$314.88Technical Performance
IOBT has shown mixed momentum, gaining 1.9% over the past week and -21.31% over the past quarter, though year-to-date performance is down -15.32%. Short-term trend indicators are bullishly aligned (SMA20 6.52%, SMA50 -23.87%, SMA200 -67.03%). The stock’s 14-day RSI is 46.2 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.13% below its high and over 74.87% above its low.
Dividend & Fair Value
IO Biotech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.88. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
IO Biotech, Inc. generated EPS of -$1.34 over the past year. Five-year average earnings growth is -25.33%. Wall Street analysts project EPS growth of 39.99% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.21. Next year's EPS is expected at $18.52. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $0.50. The high target offers 39900.0% upside. The low target suggests 4900.0% downside. The mean target is $2.50. This offers 24900.0% upside. IO Biotech, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -9.68%. The prior quarter beat by -59.63%. Over the last six quarters, Apple has recorded several small beats. These include 24.14% in November 12, 2024.
Shareholding & Insider Activity
IO Biotech, Inc. has 65.88 million shares outstanding. The public float is 31.28 million shares, elevated short interest at 2.69% of float. This equals 851.15 thousand shares. The short ratio is 1.64 days. Institutional investors hold 50.06% of the float. Insiders own 6.63%. Lundbeckfond Invest A/S holds 6.05 million shares, Novo Holdings A/S has 4.35 million shares and Vivo Capital IX, LLC has 3.16 million shares.
Frequently Asked Questions
What is the current IO Biotech, Inc. (IOBT) stock price?
IO Biotech, Inc. (NASDAQ: IOBT) stock price is $0.01 in the last trading session. During the trading session, IOBT stock reached the peak price of $0.02 while $0.01 was the lowest point it dropped to. The percentage change in IOBT stock occurred in the recent session was -27.59% while the dollar amount for the price change in IOBT stock was - $0.00.
IOBT's industry and sector of operation?
The NASDAQ listed IOBT is part of Biotechnology industry that operates in the broader Healthcare sector. IO Biotech, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of IOBT?
Dr. Eva Ehrnrooth M.D., Ph.D.
Chief Medical Officer
Anders Ljungqvist
Founder
Prof. Per Thor Straten
Founder
Prof. Inge Marie Svane M.D., Ph.D.
Founder & Clinical Advisor
Ms. Amy B. Sullivan
Chief Financial Officer
Mr. Brian Burkavage
Chief Accounting Officer
Mr. Eric Faulkner M.B.A.
Chief Technical Officer
Dr. Mai-Britt Zocca Ph.D.
Founder, Pres, Chief Executive Officer, Principal Financial Officer & Director
Prof. Mads Hald Andersen Ph.D.
Founder & Scientific Advisor
Mr. Mikkel Dybkjær
Vice President of Corporation Fin.
Dr. Muhammad Al-Hajj Ph.D.
Chief Scientific Officer
Mr. Devin Whittemore Smith
Sec., Gen. Counsel & Chief Compliance Officer
Ms. Amy B. Sullivan M.B.A.
Chief Financial Officer
Prof. Mads Hald Andersen M.D., Ph.D.
Founder & Scientific Advisor
Mr. Daniel G. Mannix Ph.D.
Senior Vice President of Regulatory Affairs
Chief Medical Officer
Anders Ljungqvist
Founder
Prof. Per Thor Straten
Founder
Prof. Inge Marie Svane M.D., Ph.D.
Founder & Clinical Advisor
Ms. Amy B. Sullivan
Chief Financial Officer
Mr. Brian Burkavage
Chief Accounting Officer
Mr. Eric Faulkner M.B.A.
Chief Technical Officer
Dr. Mai-Britt Zocca Ph.D.
Founder, Pres, Chief Executive Officer, Principal Financial Officer & Director
Prof. Mads Hald Andersen Ph.D.
Founder & Scientific Advisor
Mr. Mikkel Dybkjær
Vice President of Corporation Fin.
Dr. Muhammad Al-Hajj Ph.D.
Chief Scientific Officer
Mr. Devin Whittemore Smith
Sec., Gen. Counsel & Chief Compliance Officer
Ms. Amy B. Sullivan M.B.A.
Chief Financial Officer
Prof. Mads Hald Andersen M.D., Ph.D.
Founder & Scientific Advisor
Mr. Daniel G. Mannix Ph.D.
Senior Vice President of Regulatory Affairs
How IOBT did perform over past 52-week?
IOBT's closing price is 0% higher than its 52-week low of $0.01 where as its distance from 52-week high of $2.79 is -99.56%.
How many employees does IOBT have?
Number of IOBT employees currently stands at 80.
Link for IOBT official website?
Official Website of IOBT is: https://www.iobiotech.com
How do I contact IOBT?
IOBT could be contacted at phone 457 070 2980 and can also be accessed through its website. IOBT operates from Ole Maaløes Vej 3, Copenhagen, 2200, Denmark.
How many shares of IOBT are traded daily?
IOBT stock volume for the day was 3.06M shares. The average number of IOBT shares traded daily for last 3 months was 19.98M.
What is the market cap of IOBT currently?
The market value of IOBT currently stands at $885.69K with its latest stock price at $0.01 and 71.95M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep